CAS NO: | 2348469-43-0 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Siplizumab (CBT-501) is a humanized IgG4k monoclonal antibody againstprogrammed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 toPD-1through a competitive action. Siplizumab can be used in research ofcancer[1]. |
体外研究 (In Vitro) | Siplizumab (CBT-501) 与人 (KD=505 pM) 和猕猴 (KD=7.2 nM) 的 PD-1 具有高度特异性结合[ 1]。 |
体内研究 (In Vivo) | Siplizumab (CBT-501; ip; 每两周一次, 持续6周; MC38同系肿瘤模型小鼠) 具有抗肿瘤活性,抑瘤率达到 83%[1]。 |
CAS 号 | 2348469-43-0 |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |